General
Preferred name
LAMIVUDINE
Synonyms
CPD000466319 ()
GR109714X ()
BCH-189 ()
Triumeq-lamivudine ()
GR109714X, BCH-189 ()
(-)-lamivudine ()
Lamivudine (BCH-189) ()
Lamivudine component of dovato ()
3TC ()
Lamivudine teva ()
Lamivudina ()
BCH 189, (-)- ()
Lamivudine teva pharma b.v. ()
Lamivudine component of temixys ()
Zeffix ()
Virolam ()
Lamivudine component of dutrebis ()
Lamivudine component of combivir ()
GR 109714X ()
Lamivudine component of epzicom ()
Lamivudinum ()
Lamivudine component of cimduo ()
Lamivudine component of trizivir ()
NSC-760061 ()
Lamivudine component of symfi ()
GR-109714X ()
Lamivudine component of delstrigo ()
Lamivudine component of triumeq ()
Epivir-Hbv ()
Lamivudine component of /zidovudine teva ()
Lamivudine component of kivexa ()
Epivir ()
P&D ID
PD002940
CAS
1117764-41-6
134678-17-4
Tags
available
prodrug
drug
Approved by
FDA
PMDA
EMA
First approval
1995
Drug indication
Human immunodeficiency virus-1 infection
Human immunodeficiency virus infection
Chronic HBV infection
chronic hepatitis B virus infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lamivudine is an antiretroviral drug. It inhibits HIV-1 reverse transcriptase, and it belongs to the nucleoside reverse transcriptase inhibitors (NRTI) class of antiretriviral drugs. (GtoPdb)
PHARMACODYNAMICS Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV) to disrupt viral DNA synthesis. When phosphorylated, lamivudine can form active metabolites that compete for incorporation into viral DNA. Via DNA incorporation, lamivudine metabolites competitively inhibit the activity of the HIV reverse transcriptase enzyme and act as a chain terminator of DNA synthesis. Due to the lack of a 3'-OH group, incorporated nucleoside analogues prevent the formation of a 5' to 3' phosphodiester linkage that is essential for DNA chain elongation.
DESCRIPTION Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].
PRICE 29
DESCRIPTION Lamivudine is a cytidine analog that inhibits the reverse transcriptases of HIV1, HIV2, and hepatitis B. It is used to treat HIV-1 and HBV. (Enamine Bioactive Compounds)
DESCRIPTION Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. (TargetMol Bioactive Compound Library)
Cell lines
6
Organisms
10
Compound Sets
28
AdooQ Bioactive Compound Library
A10512
Axon Medchem Screening Library
3304
Bioprocess diversity set
Cayman Chemical Bioactives
18514
ChEMBL Approved Drugs
CHEMBL141
ChEMBL Drugs
CHEMBL141
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00709
DrugBank Approved Drugs
DB00709
DrugCentral
1539
DrugCentral Approved Drugs
1539
DrugMAP
DMI347A
DrugMAP Approved Drugs
DMI347A
Enamine Bioactive Compounds
EBC-03887
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100919
Guide to Pharmacology
12673
Mcule NIBR MoA Box Subset
MCULE-8483986532
MedChem Express Bioactive Compound Library
HY-B0250
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
2T8Q726O95
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Lamivudine(Epivir)
TargetMol Bioactive Compound Library
T0682
External IDs
54
Properties
(calculated by RDKit )
Molecular Weight
229.05
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-0.59
TPSA
90.37
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biological process
Protein degradation
Target
HIV
Reverse Transcriptase
NRT inhibitor
HBV
COVID-19,Reverse Transcriptase
Member status
member
MOA
Reverse Transcriptase Inhibitors
nucleoside reverse transcriptase inhibitor
Indication
human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B
Biosynthetic Origin
Nucleoside
Therapeutic Indication
Antiviral
Therapeutic Class
Anti-HIV Agents
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Source data